Use of imaging to assess the activity of hepatic transporters
Open Access
- 23 January 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 16 (2) , 149-164
Abstract
Introduction: Membrane transporters of the SLC and ABC families are abundantly expressed in the liver, where they control the transfer of drugs/drug metabolites across the sinusoidal and canalicular hepatocyte membranes and play a pivotal role in hepatic drug clearance. Non-invasive imaging methods, such as PET, SPECT or MRI, allow for measuring the activity of hepatic transporters in vivo, provided that suitable transporter imaging probes are available. Areas covered: We give an overview of the working principles of imaging-based assessment of hepatic transporter activity. We discuss different currently available PET/SPECT radiotracers and MRI contrast agents and their applications to measure hepatic transporter activity in health and disease. We cover mathematical modeling approaches to obtain quantitative parameters of transporter activity and provide a critical assessment of methodological limitations and challenges associated with this approach. Expert opinion: PET in combination with pharmacokinetic modeling can be potentially applied in drug development to study the distribution of new drug candidates to the liver and their clearance mechanisms. This approach bears potential to mechanistically assess transporter-mediated drug-drug interactions, to assess the influence of disease on hepatic drug disposition and to validate and refine currently available in vitro-in vivo extrapolation methods to predict hepatic clearance of drugs.Keywords
This publication has 157 references indexed in Scilit:
- Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat HepatocytesDrug Metabolism and Disposition, 2012
- [N-Methyl-11C]Cholylsarcosine, a Novel Bile Acid Tracer for PET/CT of Hepatic Excretory Function: Radiosynthesis and Proof-of-Concept Studies in PigsJournal of Nuclear Medicine, 2012
- Approaches using molecular imaging technology — use of PET in clinical microdose studiesAdvanced Drug Delivery Reviews, 2011
- Tracer input for kinetic modelling of liver physiology determined without sampling portal venous blood in pigsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Evaluation of 99mTechnetium-Mebrofenin and 99mTechnetium-Sestamibi as Specific Probes for Hepatic Transport Protein Function in Rat and Human HepatocytesPharmaceutical Research, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo ApplicationsClinical Pharmacology & Therapeutics, 2009
- Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)Journal of Experimental & Clinical Cancer Research, 2008
- Use of Tc-99m Mebrofenin as a Clinical Probe to Assess Altered Hepatobiliary Transport: Integration of In Vitro, Pharmacokinetic Modeling, and Simulation StudiesPharmaceutical Research, 2008
- Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug developmentEuropean Journal of Clinical Pharmacology, 2003